Regulation of cell proliferation through a KIT-mediated mechanism in benign prostatic hyperplasia

Prostate

Volumn 72, Issue 14, 2012, Pages 1506-1513

  Imura, Makoto ^a   Kojima, Yoshiyuki ^a   Kubota, Yasue ^a   Hamakawa, Takashi ^a   Yasui, Takahiro ^a   Sasaki, Shoichi ^a   Hayashi, Yutaro ^a   Kohri, Kenjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

benign prostatic hyperplasia; cell proliferation; interstitial cells; KIT; stem cell factor

Indexed keywords

IMATINIB; JANUS KINASE 2; STAT1 PROTEIN; STEM CELL FACTOR;

AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; STROMA CELL; UPREGULATION; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CELL GROWTH PROCESSES; CELL LINE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; JANUS KINASE 2; MALE; PIPERAZINES; PROSTATIC HYPERPLASIA; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAT1 TRANSCRIPTION FACTOR; STEM CELL FACTOR; STROMAL CELLS;

EID: 84865505958     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22500     Document Type: Article

References (26)

1. Oesterling JE,. Benign prostatic hyperplasia: A review of its histogenesis and na (Pubitemid 26112291)
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL,. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132 (3): 474-479. (Pubitemid 14026148)
3. Caine M,. Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy. Urology 1988; 32 (6 Suppl): 16-20. (Pubitemid 19013255)
4. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A,. Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 6 (11): 3341-3351.
5. Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW,. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33 (5): 459-465. (Pubitemid 34747864)
6. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H,. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347 (7): 472-480. (Pubitemid 34879334)
7. Simak R, Capodieci P, Cohen DW, Fair WR, Scher H, Melamed J, Drobnjak M, Heston WD, Stix U, Steiner G, Cordon-Cardo C,. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues. Histol Histopathol 2000; 15 (2): 365-374. (Pubitemid 30218829)
8. Van der Aa F, Roskams T, Blyweert W, De Ridder D,. Interstitial cells in the human prostate: A new therapeutic target? Prostate 2003; 56 (4): 250-255. (Pubitemid 36988745)
9. Shafik A, Shafik I, el-Sibai O,. Identification of c-kit-positive cells in the human prostate: The interstitial cells of Cajal. Arch Androl 2005; 51 (5): 345-351. (Pubitemid 41190669)
10. Okada S, Kojima Y, Kubota Y, Mizuno K, Sasaki S, Kohri K,. Attenuation of bladder overactivity in KIT mutant rats. BJU Int 2011; 108 (2 Pt 2): E97-E103.
11. Kubota Y, Hashitani H, Shirasawa N, Kojima Y, Sasaki S, Mabuchi Y, Soji T, Suzuki H, Kohri K,. Altered distribution of interstitial cells in the guinea pig bladder following bladder outlet obstruction. Neurourol Urodyn 2008; 27 (4): 330-340. (Pubitemid 351656406)
12. Pang X, Sant G, Theoharides TC,. Altered expression of bladder mast cell growth factor receptor (c-kit) in interstitial cystitis. Urology 1998; 51 (6): 939-944. (Pubitemid 28240852)
13. Lee KL, Peehl DM,. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 2004; 172 (5 Pt 1): 1784-1791. (Pubitemid 39363056)
14. Kitamura Y,. Gastrointestinal stromal tumors: Past, present, and future. J Gastroenterol 2008; 43 (7): 499-508.
15. Reber L, Da Silva CA, Frossard N,. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 2006; 533 (1-3): 327-340. (Pubitemid 43340024)
16. Halupa A, Bailey ML, Huang K, Iscove NN, Levy DE, Barber DL,. A novel role for STAT1 in regulating murine erythropoiesis: Deletion of STAT1 results in overall reduction of erythroid progenitors and alters their distribution. Blood 2005; 105 (2): 552-561. (Pubitemid 40070736)
17. Chang YP, Tsai CC, Huang WC, Wang CY, Chen CL, Lin YS, Kai JI, Hsieh CY, Cheng YL, Choi PC, Chen SH, Chang SP, Liu HS, Lin CF,. Autophagy facilitates IFN-gamma-induced Jak2-STAT1 activation and cellular inflammation. J Biol Chem 2010; 285 (37): 28715-28722.
18. Deberry C, Mou S, Linnekin D,. Stat1 associates with c-kit and is activated in response to stem cell factor. Biochem J 1997; 327 (Pt 1): 73-80. (Pubitemid 27455463)
19. Miettinen M, Lasota J,. Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130 (10): 1466-1478. (Pubitemid 44520713)
20. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349 (25): 2387-2398. (Pubitemid 37542987)
21. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F, CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-Year results from the CombAT study. Eur Urol 2010; 57 (1): 123-131.
22. Gravas S, Oelke M,. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 2010; 28 (1): 9-15.
23. Waller CF,. Imatinib mesylate. Recent Results Cancer Res 2010; 184: 3-20.
24. Breccia M, Efficace F, Alimena G,. Imatinib treatment in chronic myelogenous leukemia: What have we learned so far? Cancer Lett 2011; 300 (2): 115-121.
25. Essat M, Cooper K,. Imatinib as adjuvant therapy for gastrointestinal stromal tumors: A systematic review. Int J Cancer 2011; 128 (9): 2202-2214.
26. Grimminger F, Schermuly RT, Ghofrani HA,. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 2010; 9 (12): 956-970.